(1-Methyl-3-propenyl)piperazin | 71739-94-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (1-Methyl-3-propenyl)piperazin
• 英文别名: 1-(1-methyl-allyl)-piperazine；1-But-3-en-2-ylpiperazine
• CAS: 71739-94-1
• 化学式: C₈H₁₆N₂
• 分子量: 140.228
• InChiKey: UGCCLGCAKMDZLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1,3-丁二烯 、 哌嗪 生成 (1-Methyl-3-propenyl)piperazin
  参考文献：
  名称：

  DZHEMILEV U. M.; YAKUPOVA A. Z.; MINSKER S. K.; TOLSTIKOV G. A., ZH. ORGAN. XIMII, 1979, 15, HO 6, 1164-1169

  摘要：

  DOI：

文献信息

• [EN] PROCESS FOR THE SEPARATION OF ENANTIOMERS OF PIPERAZINE DERIVATIVES<br/>[FR] PROCÉDÉ DE SÉPARATION D'ÉNANTIOMÈRES DE DÉRIVÉS DE PIPÉRAZINE
  申请人：ASCENEURON S A

  公开号：WO2017144635A1

  公开（公告）日：2017-08-31

  The invention relates to a process for preparing either enantiomer of a compound of formula (I), wherein X, Y and n have the meaning given in claim 1, with high enantiomeric excess (e.e.), by chiral resolution in the presence of a non-racemic, chiral acid.

  该发明涉及一种制备式(I)化合物的任一对映体的方法，其中X、Y和n的含义如权利要求1所述，通过在非外消旋手性酸存在下进行手性分离，以高对映体过量（e.e.）进行。
• US4353826A
  申请人：——

  公开号：US4353826A

  公开（公告）日：1982-10-12
• [EN] COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PREVENTING SIGMA RECEPTOR RELATED DISEASES AND/OR DISORDERS<br/>[FR] COMPOSÉS, COMPOSITIONS ET MÉTHODES POUR TRAITER, ATTÉNUER ET/OU PRÉVENIR DES MALADIES ET/OU DES TROUBLES ASSOCIÉS AU RÉCEPTEUR SIGMA
  申请人：UNIV RUTGERS

  公开号：WO2021252709A1

  公开（公告）日：2021-12-16

  The disclosure relates in one aspect to methods of treating, ameliorating, and/or preventing certain S1R and/or S2R-related diseases and/or disorders, such as for example certain viral infections in a subject, comprising administering to the subject at least one of a compound of the present disclosure and a composition comprising such compounds. In another aspect, the disclosure relates to methods of treating, ameliorating, and/or preventing sigma receptor related diseases and/or disorders in a subject, comprising administering to the subject at least one of a compound of the present disclosure and a composition comprising such compounds. In certain embodiments, the subject is a mammal. In yet other embodiments, the mammal is human.